Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Pregnancy in the context of myeloproliferative neoplasms (MPN) poses unique fetal and
maternal challenges. Current literature in this regard mostly involves essential …

The combined incidence of classical Philadelphia‐negative myeloproliferative neoplasm
(MPN) is 6–9/100 000 with a peak frequency between 50 and 70 years. MPN is less frequent …

Thrombotic and hemorrhagic complications are prevalent in patients with essential
thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and …

Introduction: The management of pregnancy during the course of BCR-ABL1-negative
myeloproliferative neoplasms (MPN) is an increasingly relevant problem. This is mostly due …

Recommendations regarding management of essential thrombocythaemia rely on studies
done before the discovery of the CALR mutation. On May 20, 2020, the European …

This article presents the results of a group discussion among an ad hoc constituted Panel of
experts aimed at highlighting unmet clinical needs (UCNs) in the management of thrombotic …

Although myeloproliferative neoplasms (MPNs) are traditionally considered diseases of
adults in their sixth or seventh decade, these conditions do occur in young patients; for …

Polycythemia vera (PV) and essential thrombocythemia (ET) are the two most common
subtypes of Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). PV …